# Parsons Corp: financial statements, quarterly

PSN · NYSE · CIK 275880 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/psn.md) · [Financials](/companies/psn/financials.md) · [Filings](/companies/psn/filings.md) · [Insiders](/companies/psn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/psn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,494 d](/filings/0001193125-26-045495.md) | [1,536](/filings/0000950170-25-060544.md) | [1,670](/filings/0000950170-25-103507.md) | [1,810](/filings/0001193125-25-265659.md) | [1,734](/filings/0000950170-25-022754.md) | [1,554](/filings/0001193125-26-188862.md) | [1,584](/filings/0001193125-26-322066.md) | [1,622](/filings/0001193125-26-435045.md) | [1,604 d](/filings/0001193125-26-045495.md) | [1,491](/filings/0001193125-26-188862.md) | [1,576](/filings/0001193125-26-322066.md) | [1,651](/filings/0001193125-26-435045.md) |
| Cost of revenue | $m | [1,127 d](/filings/0001193125-26-045495.md) | [1,211](/filings/0000950170-25-060544.md) | [1,319](/filings/0000950170-25-103507.md) | [1,450](/filings/0001193125-25-265659.md) | [1,365 d](/filings/0001193125-26-045495.md) | [1,200](/filings/0001193125-26-188862.md) | [1,236](/filings/0001193125-26-322066.md) | [1,262](/filings/0001193125-26-435045.md) | [1,234 d](/filings/0001193125-26-045495.md) | [1,134](/filings/0001193125-26-188862.md) | [1,281](/filings/0001193125-26-322066.md) | [1,268](/filings/0001193125-26-435045.md) |
| Selling, general and administrative | $m | [238 d](/filings/0001193125-26-045495.md) | [221](/filings/0000950170-25-060544.md) | [223](/filings/0000950170-25-103507.md) | [246](/filings/0001193125-25-265659.md) | [265 d](/filings/0001193125-26-045495.md) | [244](/filings/0001193125-26-188862.md) | [252](/filings/0001193125-26-322066.md) | [260](/filings/0001193125-26-435045.md) | [260 d](/filings/0001193125-26-045495.md) | [268](/filings/0001193125-26-188862.md) | [260](/filings/0001193125-26-322066.md) | [285](/filings/0001193125-26-435045.md) |
| Operating income | $m | [77.4 d](/filings/0001193125-26-045495.md) | [102](/filings/0000950170-25-060544.md) | [111](/filings/0000950170-25-103507.md) | [115](/filings/0001193125-25-265659.md) | [99.8](/filings/0000950170-25-022754.md) | [109](/filings/0001193125-26-188862.md) | [95.7](/filings/0001193125-26-322066.md) | [108](/filings/0001193125-26-435045.md) | [105 d](/filings/0001193125-26-045495.md) | [95.7](/filings/0001193125-26-188862.md) | [1.3](/filings/0001193125-26-322066.md) | [104](/filings/0001193125-26-435045.md) |
| Interest expense | $m | [9.1 d](/filings/0001193125-26-045495.md) | [13.0](/filings/0000950170-25-060544.md) | [13.0](/filings/0000950170-25-103507.md) | [13.0](/filings/0001193125-25-265659.md) | [12.5 d](/filings/0001193125-26-045495.md) | [12.2](/filings/0001193125-26-188862.md) | [12.6](/filings/0001193125-26-322066.md) | [13.5](/filings/0001193125-26-435045.md) | [13.0 d](/filings/0001193125-26-045495.md) | [16.0](/filings/0001193125-26-188862.md) | [16.4](/filings/0001193125-26-322066.md) | [16.3](/filings/0001193125-26-435045.md) |
| Income tax | $m | [14.2 d](/filings/0001193125-26-045495.md) | [13.3](/filings/0000950170-25-060544.md) | [22.4](/filings/0000950170-25-103507.md) | [22.5](/filings/0001193125-25-265659.md) | [18.7](/filings/0000950170-25-022754.md) | [19.0](/filings/0001193125-26-188862.md) | [18.7](/filings/0001193125-26-322066.md) | [16.0](/filings/0001193125-26-435045.md) | [19.9 d](/filings/0001193125-26-045495.md) | [16.1](/filings/0001193125-26-188862.md) | [4.2](/filings/0001193125-26-322066.md) | [20.4](/filings/0001193125-26-435045.md) |
| Net income | $m | [44.9 d](/filings/0001193125-26-045495.md) | [39.8](/filings/0000950170-25-060544.md) | [69.2](/filings/0000950170-25-103507.md) | [72.0](/filings/0001193125-25-265659.md) | [54.2](/filings/0000950170-25-022754.md) | [66.2](/filings/0001193125-26-188862.md) | [55.2](/filings/0001193125-26-322066.md) | [64.1](/filings/0001193125-26-435045.md) | [55.6 d](/filings/0001193125-26-045495.md) | [52.9](/filings/0001193125-26-188862.md) | [(15.2)](/filings/0001193125-26-322066.md) | [54.2](/filings/0001193125-26-435045.md) |
| Diluted EPS | $ per share | not reported | [0.37](/filings/0000950170-25-060544.md) | [0.63](/filings/0000950170-25-103507.md) | [0.65](/filings/0001193125-25-265659.md) | [0.49](/filings/0000950170-25-022754.md) | [0.60](/filings/0001193125-26-188862.md) | [0.50](/filings/0001193125-26-322066.md) | [0.59](/filings/0001193125-26-435045.md) | not reported | [0.49](/filings/0001193125-26-188862.md) | [(0.14)](/filings/0001193125-26-322066.md) | [0.51](/filings/0001193125-26-435045.md) |
| Basic EPS | $ per share | not reported | [0.37](/filings/0000950170-25-060544.md) | [0.65](/filings/0000950170-25-103507.md) | [0.68](/filings/0001193125-25-265659.md) | [0.51](/filings/0000950170-25-022754.md) | [0.62](/filings/0001193125-26-188862.md) | [0.52](/filings/0001193125-26-322066.md) | [0.60](/filings/0001193125-26-435045.md) | not reported | [0.49](/filings/0001193125-26-188862.md) | [(0.14)](/filings/0001193125-26-322066.md) | [0.51](/filings/0001193125-26-435045.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [273](/filings/0000950170-25-022754.md) | [423](/filings/0000950170-24-050876.md) | [528](/filings/0000950170-24-088219.md) | [559](/filings/0000950170-24-118574.md) | [454](/filings/0001193125-26-045495.md) | [270](/filings/0000950170-25-060544.md) | [411](/filings/0000950170-25-103507.md) | [423](/filings/0001193125-25-265659.md) | [466](/filings/0001193125-26-435045.md) | [284](/filings/0001193125-26-188862.md) | [266](/filings/0001193125-26-322066.md) | [297](/filings/0001193125-26-435045.md) |
| Current assets | $m | [2,138](/filings/0000950170-25-022754.md) | [2,427](/filings/0000950170-24-050876.md) | [2,574](/filings/0000950170-24-088219.md) | [2,555](/filings/0000950170-24-118574.md) | [2,462](/filings/0001193125-26-045495.md) | [2,401](/filings/0000950170-25-060544.md) | [2,594](/filings/0000950170-25-103507.md) | [2,649](/filings/0001193125-25-265659.md) | [2,684](/filings/0001193125-26-435045.md) | [2,594](/filings/0001193125-26-188862.md) | [2,720](/filings/0001193125-26-322066.md) | [2,579](/filings/0001193125-26-435045.md) |
| Total assets | $m | [4,804](/filings/0000950170-25-022754.md) | [5,098](/filings/0000950170-24-050876.md) | [5,239](/filings/0000950170-24-088219.md) | [5,443](/filings/0000950170-24-118574.md) | [5,488](/filings/0001193125-26-045495.md) | [5,449](/filings/0000950170-25-060544.md) | [5,721](/filings/0000950170-25-103507.md) | [5,737](/filings/0001193125-25-265659.md) | [5,770](/filings/0001193125-26-435045.md) | [6,012](/filings/0001193125-26-188862.md) | [6,107](/filings/0001193125-26-322066.md) | [5,985](/filings/0001193125-26-435045.md) |
| Current liabilities | $m | [1,411](/filings/0000950170-25-022754.md) | [1,354](/filings/0000950170-24-050876.md) | [1,427](/filings/0000950170-24-088219.md) | [1,650](/filings/0000950170-24-118574.md) | [1,916](/filings/0001193125-26-045495.md) | [1,865](/filings/0000950170-25-060544.md) | [1,608](/filings/0000950170-25-103507.md) | [1,588](/filings/0001193125-25-265659.md) | [1,532](/filings/0001193125-26-435045.md) | [1,480](/filings/0001193125-26-188862.md) | [1,637](/filings/0001193125-26-322066.md) | [1,617](/filings/0001193125-26-435045.md) |
| Total liabilities | $m | [2,427](/filings/0000950170-25-022754.md) | [2,855](/filings/0000950170-24-050876.md) | [2,919](/filings/0000950170-24-088219.md) | [3,029](/filings/0000950170-24-118574.md) | [2,953](/filings/0001193125-26-045495.md) | [2,903](/filings/0000950170-25-060544.md) | [3,100](/filings/0000950170-25-103507.md) | [3,072](/filings/0001193125-25-265659.md) | [3,002](/filings/0001193125-26-435045.md) | [3,258](/filings/0001193125-26-188862.md) | [3,359](/filings/0001193125-26-322066.md) | [3,237](/filings/0001193125-26-435045.md) |
| Long-term debt | $m | [746](/filings/0000950170-25-022754.md) | [1,246](/filings/0000950170-24-050876.md) | [1,247](/filings/0000950170-24-088219.md) | [1,133](/filings/0000950170-24-118574.md) | [784](/filings/0001193125-26-045495.md) | [785](/filings/0000950170-25-060544.md) | [1,236](/filings/0000950170-25-103507.md) | [1,237](/filings/0001193125-25-265659.md) | [1,238](/filings/0001193125-26-435045.md) | [1,513](/filings/0001193125-26-188862.md) | [1,474](/filings/0001193125-26-322066.md) | [1,357](/filings/0001193125-26-435045.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | [463](/filings/0001193125-26-045495.md) | [435](/filings/0000950170-25-060544.md) | [84.9](/filings/0000950170-25-103507.md) | [0.0](/filings/0001193125-25-265659.md) | [0.0](/filings/0001193125-26-045495.md) | not reported | not reported | not reported |
| Short-term borrowings | $m | [0.0](/filings/0000950170-25-022754.md) | not reported | not reported | [115](/filings/0000950170-24-118574.md) | [463](/filings/0001193125-26-045495.md) | [435](/filings/0000950170-25-060544.md) | [84.9](/filings/0000950170-25-103507.md) | [0.0](/filings/0001193125-25-265659.md) | [0.0](/filings/0001193125-26-045495.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [2,287](/filings/0000950170-25-022754.md) | [2,150](/filings/0000950170-24-050876.md) | [2,219](/filings/0000950170-24-088219.md) | [2,312](/filings/0000950170-24-118574.md) | [2,416](/filings/0001193125-26-045495.md) | [2,454](/filings/0000950170-25-060544.md) | [2,516](/filings/0000950170-25-103507.md) | [2,558](/filings/0001193125-25-265659.md) | [2,642](/filings/0001193125-26-435045.md) | [2,650](/filings/0001193125-26-188862.md) | [2,631](/filings/0001193125-26-322066.md) | [2,638](/filings/0001193125-26-435045.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [190 d](/filings/0001193125-26-045495.md) | [(63.4)](/filings/0000950170-25-060544.md) | [161 d](/filings/0000950170-25-103507.md) | [299 d](/filings/0001193125-25-265659.md) | [127 d](/filings/0001193125-26-045495.md) | [(11.8)](/filings/0001193125-26-188862.md) | [160 d](/filings/0001193125-26-322066.md) | [163 d](/filings/0001193125-26-435045.md) | [168 d](/filings/0001193125-26-045495.md) | [(3.7)](/filings/0001193125-26-188862.md) | [57.6 d](/filings/0001193125-26-322066.md) | [269 d](/filings/0001193125-26-435045.md) |
| Capital expenditure | $m | [9.5 d](/filings/0001193125-26-045495.md) | [9.4](/filings/0000950170-25-060544.md) | [9.3 d](/filings/0000950170-25-103507.md) | [11.7 d](/filings/0001193125-25-265659.md) | [18.8 d](/filings/0001193125-26-045495.md) | [13.5](/filings/0001193125-26-188862.md) | [9.4 d](/filings/0001193125-26-322066.md) | [13.1 d](/filings/0001193125-26-435045.md) | [31.9 d](/filings/0001193125-26-045495.md) | [14.9](/filings/0001193125-26-188862.md) | [16.1 d](/filings/0001193125-26-322066.md) | [17.9 d](/filings/0001193125-26-435045.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [3.0 d](/filings/0001193125-26-045495.md) | [0.0](/filings/0000950170-25-060544.md) | [10.0 d](/filings/0000950170-25-103507.md) | [0.0 d](/filings/0001193125-25-265659.md) | [15.0 d](/filings/0001193125-26-045495.md) | [25.0](/filings/0001193125-26-188862.md) | [15.0 d](/filings/0001193125-26-322066.md) | [25.0 d](/filings/0001193125-26-435045.md) | [60.0 d](/filings/0001193125-26-045495.md) | [35.0](/filings/0001193125-26-188862.md) | [15.0 d](/filings/0001193125-26-322066.md) | [60.0 d](/filings/0001193125-26-435045.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [115](/filings/0000950170-24-050876.md) | [115](/filings/0000950170-24-088219.md) | [115](/filings/0000950170-24-118574.md) | [114](/filings/0000950170-25-060544.md) | [111](/filings/0000950170-25-103507.md) | [111](/filings/0001193125-25-265659.md) | [111](/filings/0001193125-26-188862.md) | [110](/filings/0001193125-26-322066.md) | [109](/filings/0001193125-26-435045.md) | [108](/filings/0001193125-26-188862.md) | [108](/filings/0001193125-26-322066.md) | [107](/filings/0001193125-26-435045.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 105,538,883 at 2026-10-20, from the cover of the [10-Q filed 2026-10-28](/filings/0001193125-26-435045.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 28, 2026, 07:54 ET. No prices; not investment advice.